Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:AST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASTAsterias Biotherapeutics$0.00$0.00$0.51▼$2.05$111KN/A136,653 shs1,000 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASTAsterias Biotherapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASTAsterias Biotherapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASTAsterias BiotherapeuticsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASTAsterias BiotherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASTAsterias BiotherapeuticsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASTAsterias BiotherapeuticsN/AInsider OwnershipCompanyInsider OwnershipASTAsterias BiotherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASTAsterias BiotherapeuticsN/A55.66 millionN/ANot OptionableAST, SENX, BLVN, and DELT HeadlinesRecent News About These CompaniesAsterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury StudyAugust 19, 2024 | br.advfn.comAsterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small C...August 19, 2024 | br.advfn.comARTV Artiva Biotherapeutics, Inc.August 13, 2024 | seekingalpha.comProcessa Pharmaceuticals Names Russell L. Skibsted as Chief Financial OfficerJuly 19, 2024 | markets.businessinsider.comApplications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud ServicesMay 20, 2024 | businesswire.comBritish & American Investment Trust Plc - Annual Financial ReportApril 30, 2024 | uk.finance.yahoo.comCLDI Calidi Biotherapeutics, Inc.March 27, 2024 | seekingalpha.comProtalix BioTherapeutics Inc PLXFebruary 17, 2024 | morningstar.comCalidi Biotherapeutics Stock (AMEX:CLDI) Dividends: History, Yield and DatesNovember 27, 2023 | benzinga.comBarinthus Biotherapeutics PLC ADRNovember 22, 2023 | morningstar.comCalidi Biotherapeutics Inc Ordinary Shares - Class ANovember 2, 2023 | morningstar.comArcutis Biotherapeutics Stock (NASDAQ:ARQT), Analyst Ratings, Price Targets, PredictionsJuly 18, 2023 | benzinga.comIovance Biotherapeutics (NASDAQ: IOVA)May 21, 2023 | fool.comHuman Embryonic Stem Cells (HESC) Market Future Investments and Forecast Till 2030May 11, 2023 | marketwatch.comBrightPath Biotherapeutics Co Ltd (4594)May 8, 2023 | investing.comBrightPath Biotherapeutics Co., Ltd.April 27, 2023 | asia.nikkei.comHuman Embryonic Stem Cells (HESC) Market: Analyzing Growth Opportunities and Industry Trends for 2023-2028March 14, 2023 | marketwatch.com2023-2029 Human Embryonic Stem Cells (HESC) Market Size and Regional Analysis | Research Report by Absolute ReportsMarch 9, 2023 | marketwatch.comStem Cell Therapy for Osteoarthritis Market Expert Industrial Investigation Report 2023-2028March 7, 2023 | marketwatch.comTherapeutic Cancer Vaccines Market 2023 | Global Industry Report Forecast 2029March 6, 2023 | marketwatch.comNew MarketBeat Followers Over TimeTop HeadlinesView All HeadlinesNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?5 Stocks That Crushed Earnings and Guidance ForecastsBy Thomas Hughes | May 8, 2025View 5 Stocks That Crushed Earnings and Guidance ForecastsUPS Stock Forecast: Rebound Underway for United Parcel Service?By Thomas Hughes | May 4, 2025View UPS Stock Forecast: Rebound Underway for United Parcel Service?Analysts and Institutions Continue to Bet Big on AlphabetBy Ryan Hasson | May 16, 2025View Analysts and Institutions Continue to Bet Big on AlphabetAmazon: Why May Is the Last Month to Get the Stock at a DiscountBy Sam Quirke | May 19, 2025View Amazon: Why May Is the Last Month to Get the Stock at a DiscountAST, SENX, BLVN, and DELT Company DescriptionsAsterias Biotherapeutics NYSEAMERICAN:AST$0.0020 0.00 (0.00%) As of 07/10/2019Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
